Ogden Christopher 4

What Happened

• CytomX CFO Christopher Ogden received equity awards on 2026-02-02 consisting of 90,000 shares (RSUs) and 325,000 derivative awards (total 415,000). All awards were granted at $0.00 per share (i.e., no cash paid at grant).
• Part of the 325,000 derivative award includes 239,987 RSUs; the remaining portion is subject to a four-year monthly vesting schedule (1/48th vesting each month beginning 2026-02-02). A separate RSU tranche vests 1/3 annually on March 15, with the first 1/3 vesting March 15, 2027, subject to continued service.

Key Details

• Transaction date: 2026-02-02; Filing date: 2026-02-04 (timely).
• Price: $0.00 per share; total immediate cash value at grant: $0.
• Awards: 90,000 RSUs + 325,000 derivative awards = 415,000 total; F2 notes 239,987 of the 325,000 are RSUs; F3 describes 1/48th monthly vesting for the option portion.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 = RSUs with 1/3 annual vesting on March 15 (first vest 3/15/2027); F2 = includes 239,987 RSUs; F3 = option-style vesting of 1/48th per month from 2/2/2026 to full vest at four years.
• Filing timeliness: appears timely (filed two days after transaction).

Context

• These are compensation grants (awards), not open-market purchases or sales. RSUs convert to common shares only as they vest; option-style awards vest over time and must generally be exercised to become shares.
• Grants like this are common for executive compensation and do not by themselves indicate an intent to buy or sell stock in the market.